A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
A phase 2 trial of Zanidatamab in oesophageal cancer and colorectal cancer, run by Jazz Pharmaceuticals, now recruiting.
Overview
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors is a phase 2 interventional study registered as NCT06695845 by Jazz Pharmaceuticals, with 200 participants planned, started 2025-01-14 and due to reach its primary completion in 2026-12-31. Interventions recorded: Zanidatamab. Conditions listed: Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialDose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Shares Endometrial cancer, Oesophageal cancer, Colorectal cancer.
- TrialStudy of GV20-0251 in Participants With Solid Tumor Malignancies
Shares Endometrial cancer, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
- TrialA Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Shares Zanidatamab, Jazz Pharmaceuticals.
- TrialA Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment o
Shares Zanidatamab, Jazz Pharmaceuticals.
- TrialA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
Shares Endometrial cancer, Colorectal cancer, Non-small-cell lung cancer.
- Trial177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Shares Endometrial cancer, Colorectal cancer, Non-small-cell lung cancer.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Endometrial cancer, Colorectal cancer.